191 related articles for article (PubMed ID: 36685563)
1. Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon.
Wang P; Mo Z; Zhang Y; Guo C; Chikede TK; Chen D; Lei Z; Gao Z; Zhang Q; Tong Q
Front Immunol; 2022; 13():1104329. PubMed ID: 36685563
[TBL] [Abstract][Full Text] [Related]
2. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis.
Zhang W; Xing M; Sun W; Chen J; Xie N; Cai Y; Wang Y; Li N; Jiang Y; Zhang F; Wang Y; Zeng Q; Ji Y; Xu C; Jiang C; Song J; Li G
J Viral Hepat; 2023 May; 30(5):427-436. PubMed ID: 36562258
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients.
Wang WX; Jia R; Jin XY; Li X; Zhou SN; Zhang XN; Zhou CB; Wang FS; Fu J
Front Immunol; 2023; 14():1121778. PubMed ID: 36756119
[TBL] [Abstract][Full Text] [Related]
4. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
[No Abstract] [Full Text] [Related]
5. [Analysis of the therapeutic efficacy and factors influencing sequential combination of nucleos(t)ide analogues with pegylated interferon alpha for 48~96 weeks in the treatment of patients with chronic hepatitis B].
Jia R; Wang WX; Zhou ZP; Nie WM; Cheng YQ; Zhao J; Lian F; Luan JQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1290-1296. PubMed ID: 38253073
[No Abstract] [Full Text] [Related]
6. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.
Li WC; Wang MR; Kong LB; Ren WG; Zhang YG; Nan YM
BMC Infect Dis; 2011 Jun; 11():165. PubMed ID: 21651820
[TBL] [Abstract][Full Text] [Related]
8. [A study of the clinical curative effect of nucleos(t)ide analogues treated to pegylated interferon-α add-on therapy in patients with chronic hepatitis B].
Liang H; Wang C; Zhu PF; Zeng QL; Huang XB; Pan YF; Pan YJ; Hu QY; Luo X; Chen H; Yu ZJ; Lu FM; Lyu J
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1297-1305. PubMed ID: 38253074
[No Abstract] [Full Text] [Related]
9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
10. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
11. Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.
Liu Y; Ren S; Ma L; Lin X; Lu J; Cao Z; Zheng S; Hu Z; Xu X; Chen X
Virol J; 2024 Mar; 21(1):77. PubMed ID: 38555445
[TBL] [Abstract][Full Text] [Related]
12. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
Zhang Y; Chen B; Wang L; Chi J; Song S; Liu M; Zhao Z
Rev Esp Enferm Dig; 2016 May; 108(5):263-70. PubMed ID: 27023755
[TBL] [Abstract][Full Text] [Related]
13. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
14. LAG3
Pang XQ; Li X; Zhu WH; Huang RK; Mo ZS; Huang ZX; Zhang Y; Xie DY; Gao ZL
Antiviral Res; 2023 May; 213():105592. PubMed ID: 37004734
[TBL] [Abstract][Full Text] [Related]
15. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
16. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
[TBL] [Abstract][Full Text] [Related]
17. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B.
Guan G; Zhang T; Ning J; Tao C; Gao N; Zeng Z; Guo H; Chen CC; Yang J; Zhang J; Gu W; Yang E; Liu R; Guo X; Ren S; Wang L; Wei G; Zheng S; Gao Z; Chen X; Lu F; Chen X
J Hepatol; 2024 Jan; 80(1):41-52. PubMed ID: 37858684
[TBL] [Abstract][Full Text] [Related]
18. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
19. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
[TBL] [Abstract][Full Text] [Related]
20. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
